Remove 2014 Remove Competition Remove Safety
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Competition starts to heat up. Classic treatment options. Two decades of exclusivity.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

The FDA’s role in the regulation of botanical drug products includes an assessment of their safety and efficiency 5 but insufficient evidence for efficacy is one of the most common reasons why new drug candidates fail to reach this step. 10,12 The THR scheme is also limited to products used for oral or external use and/or inhalation.

Marketing 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. EMA Guideline on Similar Biological Medicinal Products, 23 October 2014, CHMP/437/04 Rev 1. The Impact of Biosimilar Competition in Europe, IQVIA, December 2021.

article thumbnail

BMS scores first approval for psoriasis therapy Sotyktu

pharmaphorum

Analysts at Mizuho have suggested that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion, although Amgen is attempting to defend its product by expanded the label of the drug to include mild psoriasis. It had been approved since 2014 for moderate to severe cases only.

FDA 52
article thumbnail

Indication Expansion: Pioneering new uses for existing cancer drugs

Clarivate

Drug repurposing, or drug repositioning, aims to identify existing drugs—either those already on the market or those that have passed human safety assessments—that can be used to treat conditions other than those they were originally developed for. The use of RWD in the drug discovery process spans many stages.

article thumbnail

Five potential EU regulatory changes impacting the life sciences industry in 2023

European Pharmaceutical Review

Regulation of clinical trials Eight years following its adoption in 2014, the Clinical Trials Regulation 536/2014 (CTR) entered into application on 31 January 2022. In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR.

Medical 117
article thumbnail

Medical Sales In Sterile Processing And Infection Prevention With Mark Copeland

Evolve Your Success

He also talks about partnering with small businesses and how they are leading the competition in this particular space. I left them in 2014 to start our own thing. Patient safety is to do no harm. I finally figured some things out and broke through then did that for ten years and they blew up. Probably right around it.